VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:VX1 - US92532F1003 - Common Stock
383.1 EUR
+0.85 (+0.22%)
We assign a fundamental rating of 6 out of 10 to VX1. VX1 was compared to 83 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making VX1 a very profitable company, without any liquidiy or solvency issues. VX1 is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, VX1 could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
- In the past year VX1 was profitable.
- VX1 had a positive operating cash flow in the past year.
- VX1 had positive earnings in 4 of the past 5 years.
- Of the past 5 years VX1 4 years had a positive operating cash flow.
1.2 Ratios
- With an excellent Return On Assets value of 14.78%, VX1 belongs to the best of the industry, outperforming 87.95% of the companies in the same industry.
- The Return On Equity of VX1 (21.22%) is better than 91.57% of its industry peers.
- VX1 has a Return On Invested Capital of 15.66%. This is amongst the best in the industry. VX1 outperforms 92.77% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for VX1 is above the industry average of 12.74%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.78% | ||
| ROE | 21.22% | ||
| ROIC | 15.67% |
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.53%
ROIC(5y)18.06%
1.3 Margins
- Looking at the Profit Margin, with a value of 31.35%, VX1 belongs to the top of the industry, outperforming 87.95% of the companies in the same industry.
- With an excellent Operating Margin value of 38.70%, VX1 belongs to the best of the industry, outperforming 93.98% of the companies in the same industry.
- In the last couple of years the Operating Margin of VX1 has grown nicely.
- VX1 has a Gross Margin of 86.28%. This is in the better half of the industry: VX1 outperforms 78.31% of its industry peers.
- In the last couple of years the Gross Margin of VX1 has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 38.7% | ||
| PM (TTM) | 31.35% | ||
| GM | 86.28% |
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
2. Health
2.1 Basic Checks
- VX1 has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- VX1 has less shares outstanding than it did 1 year ago.
- The number of shares outstanding for VX1 has been reduced compared to 5 years ago.
- Compared to 1 year ago, VX1 has an improved debt to assets ratio.
2.2 Solvency
- There is no outstanding debt for VX1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | N/A |
ROIC/WACC1.76
WACC8.88%
2.3 Liquidity
- VX1 has a Current Ratio of 2.36. This indicates that VX1 is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of VX1 (2.36) is comparable to the rest of the industry.
- A Quick Ratio of 2.00 indicates that VX1 should not have too much problems paying its short term obligations.
- VX1 has a Quick ratio (2.00) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.36 | ||
| Quick Ratio | 2 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 3303.92% over the past year.
- The earnings per share for VX1 have been decreasing by -44.14% on average. This is quite bad
- The Revenue has grown by 10.33% in the past year. This is quite good.
- Measured over the past years, VX1 shows a very strong growth in Revenue. The Revenue has been growing by 21.50% on average per year.
EPS 1Y (TTM)3303.92%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%9.59%
Revenue 1Y (TTM)10.33%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%10.99%
3.2 Future
- VX1 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 150.51% yearly.
- Based on estimates for the next years, VX1 will show a quite strong growth in Revenue. The Revenue will grow by 9.75% on average per year.
EPS Next Y6343.89%
EPS Next 2Y739.72%
EPS Next 3Y328.89%
EPS Next 5Y150.51%
Revenue Next Year10.07%
Revenue Next 2Y9.25%
Revenue Next 3Y9.32%
Revenue Next 5Y9.75%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 25.64 indicates a quite expensive valuation of VX1.
- Compared to the rest of the industry, the Price/Earnings ratio of VX1 indicates a somewhat cheap valuation: VX1 is cheaper than 79.52% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.47, VX1 is valued at the same level.
- The Price/Forward Earnings ratio is 21.76, which indicates a rather expensive current valuation of VX1.
- Based on the Price/Forward Earnings ratio, VX1 is valued cheaply inside the industry as 81.93% of the companies are valued more expensively.
- When comparing the Price/Forward Earnings ratio of VX1 to the average of the S&P500 Index (24.26), we can say VX1 is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.64 | ||
| Fwd PE | 21.76 |
4.2 Price Multiples
- 77.11% of the companies in the same industry are more expensive than VX1, based on the Enterprise Value to EBITDA ratio.
- Based on the Price/Free Cash Flow ratio, VX1 is valued cheaply inside the industry as 83.13% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 33.84 | ||
| EV/EBITDA | 22.51 |
4.3 Compensation for Growth
- VX1's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of VX1 may justify a higher PE ratio.
- A more expensive valuation may be justified as VX1's earnings are expected to grow with 328.89% in the coming years.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y739.72%
EPS Next 3Y328.89%
5. Dividend
5.1 Amount
- No dividends for VX1!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:VX1 (1/16/2026, 7:00:00 PM)
383.1
+0.85 (+0.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03 2025-11-03/amc
Earnings (Next)02-09 2026-02-09/amc
Inst Owners97.56%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap97.20B
Revenue(TTM)11.72B
Net Income(TTM)3.68B
Analysts76.92
Price Target434.26 (13.35%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.29%
Min EPS beat(2)3.12%
Max EPS beat(2)3.45%
EPS beat(4)2
Avg EPS beat(4)-0.92%
Min EPS beat(4)-7.2%
Max EPS beat(4)3.45%
EPS beat(8)5
Avg EPS beat(8)-64.05%
EPS beat(12)7
Avg EPS beat(12)-42.39%
EPS beat(16)10
Avg EPS beat(16)-31.28%
Revenue beat(2)1
Avg Revenue beat(2)-0.58%
Min Revenue beat(2)-1.21%
Max Revenue beat(2)0.06%
Revenue beat(4)2
Avg Revenue beat(4)-0.82%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)2.68%
Revenue beat(8)3
Avg Revenue beat(8)-0.69%
Revenue beat(12)4
Avg Revenue beat(12)-0.78%
Revenue beat(16)7
Avg Revenue beat(16)-0.32%
PT rev (1m)0.95%
PT rev (3m)3.79%
EPS NQ rev (1m)-0.35%
EPS NQ rev (3m)3.71%
EPS NY rev (1m)0.02%
EPS NY rev (3m)1.53%
Revenue NQ rev (1m)-0.06%
Revenue NQ rev (3m)-0.92%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)0.01%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.64 | ||
| Fwd PE | 21.76 | ||
| P/S | 9.63 | ||
| P/FCF | 33.84 | ||
| P/OCF | 30.37 | ||
| P/B | 6.52 | ||
| P/tB | 7.15 | ||
| EV/EBITDA | 22.51 |
EPS(TTM)14.94
EY3.9%
EPS(NY)17.6
Fwd EY4.59%
FCF(TTM)11.32
FCFY2.96%
OCF(TTM)12.61
OCFY3.29%
SpS39.77
BVpS58.76
TBVpS53.61
PEG (NY)0
PEG (5Y)N/A
Graham Number140.54
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.78% | ||
| ROE | 21.22% | ||
| ROCE | 22.25% | ||
| ROIC | 15.67% | ||
| ROICexc | 22.65% | ||
| ROICexgc | 25.38% | ||
| OM | 38.7% | ||
| PM (TTM) | 31.35% | ||
| GM | 86.28% | ||
| FCFM | 28.47% |
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.53%
ROIC(5y)18.06%
ROICexc(3y)43.35%
ROICexc(5y)48.92%
ROICexgc(3y)62.02%
ROICexgc(5y)75.97%
ROCE(3y)24.89%
ROCE(5y)25.65%
ROICexgc growth 3Y-29.98%
ROICexgc growth 5Y-9.76%
ROICexc growth 3Y-22.64%
ROICexc growth 5Y-1.94%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
F-Score7
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 189.83% | ||
| Cap/Sales | 3.25% | ||
| Interest Coverage | 374.91 | ||
| Cash Conversion | 78.49% | ||
| Profit Quality | 90.81% | ||
| Current Ratio | 2.36 | ||
| Quick Ratio | 2 | ||
| Altman-Z | N/A |
F-Score7
WACC8.88%
ROIC/WACC1.76
Cap/Depr(3y)171.61%
Cap/Depr(5y)187.83%
Cap/Sales(3y)3.11%
Cap/Sales(5y)3.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3303.92%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%9.59%
EPS Next Y6343.89%
EPS Next 2Y739.72%
EPS Next 3Y328.89%
EPS Next 5Y150.51%
Revenue 1Y (TTM)10.33%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%10.99%
Revenue Next Year10.07%
Revenue Next 2Y9.25%
Revenue Next 3Y9.32%
Revenue Next 5Y9.75%
EBIT growth 1Y5.79%
EBIT growth 3Y16.47%
EBIT growth 5Y29.7%
EBIT Next Year811.13%
EBIT Next 3Y128.24%
EBIT Next 5Y70.14%
FCF growth 1Y-20.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.14%
OCF growth 3YN/A
OCF growth 5YN/A
VERTEX PHARMACEUTICALS INC / VX1.DE FAQ
What is the ChartMill fundamental rating of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?
ChartMill assigns a fundamental rating of 6 / 10 to VX1.DE.
What is the valuation status for VX1 stock?
ChartMill assigns a valuation rating of 6 / 10 to VERTEX PHARMACEUTICALS INC (VX1.DE). This can be considered as Fairly Valued.
What is the profitability of VX1 stock?
VERTEX PHARMACEUTICALS INC (VX1.DE) has a profitability rating of 7 / 10.
How financially healthy is VERTEX PHARMACEUTICALS INC?
The financial health rating of VERTEX PHARMACEUTICALS INC (VX1.DE) is 7 / 10.
What is the earnings growth outlook for VERTEX PHARMACEUTICALS INC?
The Earnings per Share (EPS) of VERTEX PHARMACEUTICALS INC (VX1.DE) is expected to grow by 6343.89% in the next year.